Screener
Nektar Therapeutics NKTR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -257.8%— | -242%— | -253.7%— | —— | —— | |
| Net margin | -287.8%-115pp | -284.2%-123pp | -297.1%-169pp | -204.5%-23.8pp | -172.9%+17.2pp | |
| Returns | ||||||
| Return on invested capital | -27%+66.2pp | -35.4%+39.8pp | -86%-23.8pp | -71%+0.8pp | -93.2%-26.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.1×-0.2× | 0.2×-0.1× | 0.2×0.0× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.4×+7.8× | 10.2×+7.0× | 5×+0.7× | 4.2×0.0× | 2.6×-2.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×— | 0.1×-7.2× | 1×-0.7× | 1.1×-1.1× | —— | |
| Per Share | ||||||
| Book value per share | $27.32+1,690% | $23.29+2,285% | $5.32+20.2% | $4.49+28.2% | -$1.72-130% | |
| Valuation | ||||||
| Market capitalization | $1.6B+39.4% | $2.06B+1,531% | $860.04M+401% | $1.08B+299% | $303.35M+25.6% | |
| Price / sales | 29.4×+11.0× | 37.1×+35.7× | 15.6×+13.8× | 17.3×+14.4× | 4×+1.5× | |
| Price / book | 1.8×-11.7× | 3.6×-5.6× | 9.6×+6.7× | 12.7×+7.2× | —— |
FAQ
- What are Nektar Therapeutics's profit margins?
- Nektar Therapeutics (NKTR) runs a 100.0% gross margin and a -257.8% operating margin, with a -287.8% net margin.
- Where do Nektar Therapeutics's ratios come from?
- Every ratio is computed from Nektar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
